1. Home
  2. ENTA vs PNNT Comparison

ENTA vs PNNT Comparison

Compare ENTA & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.15

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$4.66

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
PNNT
Founded
1995
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
397.7M
IPO Year
2012
2007

Fundamental Metrics

Financial Performance
Metric
ENTA
PNNT
Price
$12.15
$4.66
Analyst Decision
Strong Buy
Hold
Analyst Count
5
5
Target Price
$20.40
$5.85
AVG Volume (30 Days)
147.1K
732.7K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
20.91%
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.14
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$4.54
52 Week High
$17.15
$7.53

Technical Indicators

Market Signals
Indicator
ENTA
PNNT
Relative Strength Index (RSI) 39.11 38.81
Support Level $12.09 N/A
Resistance Level $15.52 $4.93
Average True Range (ATR) 0.63 0.15
MACD -0.17 0.01
Stochastic Oscillator 7.62 28.26

Price Performance

Historical Comparison
ENTA
PNNT

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

Share on Social Networks: